Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

2022101 citationsJournal Articlebronze Open Access

Authors

Olivier J. van Not · Dutch Institute for Clinical Auditing

Rik J. Verheijden · University Medical Center Utrecht

Alfonsus Johannes Maria van den Eertwegh · Cancer Center Amsterdam

John B.A.G. Haanen · The Netherlands Cancer Institute

Maureen J.B. Aarts · Maastricht University Medical Centre

Franchette W.P.J. van den Berkmortel · Zuyderland Medisch Centrum

Christian U. Blank

Abstract

In this cohort study, second-line immunosuppression for irAEs was associated with impaired PFS, OS, and MSS in patients with advanced melanoma treated with first-line ipilimumab and nivolumab. These findings stress the importance of assessing the effects of differential irAE management strategies, not only in patients with melanoma but also other tumor types.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Oncology

Volume 8, Issue 12, pp. 1794-1794

DOI: 10.1001/jamaoncol.2022.5041

Field-Weighted Citation Impact: 9.64

Command Palette